BLACK WEEKSVialer −15% · kit −10% · övrigt −5%med kodFri frakt inom Tyskland från €200

Den här sidan har översatts automatiskt och kan innehålla fel. Har du svenska som modersmål? Vi tar gärna emot din feedback och dina förbättringar.Skicka feedback

The Peptide Desk The Peptide Desk
Reta + Cagri Blend, produktfoto
GLP-1

Reta + Cagri Blend

GLP-1

  • Skickas från Tyskland

Beställning

Styckpris - Fri frakt inom Tyskland från 200 € under Black Weeks
  • DHL med spårning
  • Diskret förpackning

4.6 av 5 på Trustpilot73 omdömen

I korthet

Reta + Cagri Blend i siffror

Nyckeltalen från vårt lexikon.

Hela lexikonartikeln
Class
Triple agonistGLP-1 / GIP / glucagon, + amylin analog
Half-life
Retatrutide around 6 dayscagrilintide around 7 to 8 days
Form
Lyophilisatepowder, reconstituted with BAC water
Sizes
30 mg1 size in the shop

Det finns ännu ingen labbanalys för Reta + Cagri Blend. Rösta på denLåt testa själv, vi betalar halvaAlla labbanalyser

Kunskap

Allt om Reta + Cagri Blend

Bra att ha

Vad du behöver till den

Bakteriostatiskt vatten läggs automatiskt i din varukorg. Sprutor och sudd med ett klick.

Insulinsprutor

10 st. · 5.50 €

Spritsuddar

50 st. · 10 €

Hur mycket vatten?

Enheter på sprutan för din vialstorlek.

Öppna kalkylatorn →

FAQ

Vanliga frågor

Källor till varje svar: lexikonartikel

Har du fortfarande en fråga?

Skriv till oss, vårt team hjälper dig.

Is the Reta + Cagri Blend approved or studied?

No. As of 26 October 2026 the registry ClinicalTrials.gov lists no trial with Retatrutide and cagrilintide together. Both components are in phase 3 and not approved.

Why Retatrutide and cagrilintide together?

Both act on different satiety pathways: Retatrutide on GLP-1, GIP and glucagon, cagrilintide on amylin receptors. With semaglutide as the partner, weight loss in a phase 1b trial after 20 weeks was 17.1 instead of 9.8 percent. For Retatrutide as the partner there are no data.

What do the studies of the components show?

Retatrutide alone: in TRIUMPH-1 after 80 weeks 25.0 percent less body weight on average at the highest study dose, 3.9 percent on placebo. Cagrilintide alone: up to 10.8 percent after 26 weeks in phase 2, 3.0 percent on placebo. In a substudy liver fat also fell sharply on Retatrutide.

Why is the cagrilintide share so small?

The vial contains five times as much Retatrutide as cagrilintide, because Retatrutide is the stronger and limiting part. Anyone going by the Retatrutide share stays far below the amounts used in the cagrilintide trials. Whether the small share contributes anything has not been studied.

How long do the components stay in the body?

Retatrutide had a half-life of about six days in a phase 1b study, cagrilintide 159 to 195 hours in another study, so about a week. Both fit one dose per week.

Which side effects were seen with the components?

With both, mainly gastrointestinal effects such as nausea and diarrhoea, depending on the dose. On Retatrutide heart rate rose in a dose-dependent way in phase 2. Two satiety signals together may strengthen nausea at the start, this has not been measured for this blend.

Which trials are still running?

Nine phase 3 trials of Retatrutide are running, the largest on heart and kidney events until 2029. The RENEW trials of cagrilintide alone run until 2027. No trial of the blend is listed in the registry.

Relaterat

Relaterade produkter